Articles related to CAR T-CELL THERAPIES

An updated review of multiple myeloma management highlights revised high-risk definitions, anti-CD38-based quadruplet induction regimens, evolving maintenance strategies, and increasing use of CAR-T and bispecific immunotherapies across the disease continuum.

Late-breaking sessions at AAN 2026 spanned rare disease, migraine prevention, epilepsy, FTD, MS, early Alzheimer’s, neuropathic pain, and stiff person syndrome, with mixed signals across disease-modifying and symptomatic therapies.

“We are surprised and disappointed by this FDA decision for EBV+ PTLD patients who have a significant unmet need, highlighted by tabelecleucel’s orphan drug designation and by the granting of breakthrough status.” — Dr. Cokey Nguyen, Atara CEO

“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

Despite poor prognosis at treatment initiation, extended follow-up reveals sustained remissions suggesting curative potential in heavily pretreated CLL patients receiving CD19-directed cellular immunotherapy.